Pirfenidone
Aliases
Esbriet
8 clinical trials
2 abstracts
18 indications
Indication
lung cancerIndication
Lung CancerIndication
Advanced CancerIndication
Metastatic Lung CancerIndication
COVID-19Indication
ARDSIndication
Head and Neck Squamous Cell CarcinomaIndication
RadiotherapyIndication
radiosensitizerIndication
PirfenidoneIndication
Multiple SclerosisIndication
Coal Workers' PneumoconiosisIndication
Acute PancreatitisIndication
NSCLCIndication
Colorectal CarcinomaIndication
Colorectal CancerIndication
Colorectal cancerAbstract
Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.Org: Department of Pancreatobiliary Surgery,
Abstract
Preliminary results of atezolizumab and pirfenidone in non-small cell lung cancer.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science,
Clinical trial
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLCStatus: Active (not recruiting), Estimated PCD: 2021-05-09
Clinical trial
Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot TrialStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
Application of Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma: Phase II Clinical StudyStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Circulating Biomarkers of Fibrosis and Cardiovascular Disease in Patients With Heart Failure With Preserved Ejection Fraction - Analysis of Samples Collected as Part of the PIROUETTE TrialStatus: Completed, Estimated PCD: 2019-11-29
Clinical trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis Associated With Radiographic and Functional Impairment to Examine the Reduction in Progression of Disease, Reduction of Exacerbation Rates and Possible Reduction of Inflammatory Biomarkers as an Index of Clinical Response.Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.Status: Not yet recruiting, Estimated PCD: 2028-02-01
Clinical trial
A Randomized Phase 1b/2 Clinical Trial Evaluating Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal CarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-07-22